These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 11081567)

  • 1. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.
    Grem JL
    Invest New Drugs; 2000 Nov; 18(4):299-313. PubMed ID: 11081567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Action and Modulation of Fluorouracil.
    Grem JL
    Semin Radiat Oncol; 1997 Oct; 7(4):249-259. PubMed ID: 10717222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
    Cao S; Frank C; Rustum YM
    J Natl Cancer Inst; 1996 Apr; 88(7):430-6. PubMed ID: 8618234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of leucovorin dosing and administration schedule.
    Jolivet J
    Eur J Cancer; 1995; 31A(7-8):1311-5. PubMed ID: 7577042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer.
    van Laar JA; Rustum YM; Ackland SP; van Groeningen CJ; Peters GJ
    Eur J Cancer; 1998 Feb; 34(3):296-306. PubMed ID: 9640213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine as an effector in radiation-activated prodrugs.
    Shibamoto Y; Mimasu Y; Tachi Y; Hatta H; Nishimoto S
    J Chemother; 2002 Aug; 14(4):390-6. PubMed ID: 12420858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to 5-fluorouracil.
    Mader RM; Müller M; Steger GG
    Gen Pharmacol; 1998 Nov; 31(5):661-6. PubMed ID: 9809460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
    Grem JL
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
    Rich TA; Shepard RC; Mosley ST
    J Clin Oncol; 2004 Jun; 22(11):2214-32. PubMed ID: 15169811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
    Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
    Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.
    Tsume Y; Provoda CJ; Amidon GL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(13-14):915-20. PubMed ID: 21450537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.
    Shibamoto Y; Tachi Y; Tanabe K; Hatta H; Nishimoto S
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):397-402. PubMed ID: 14751508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
    Sotos GA; Grogan L; Allegra CJ
    Cancer Treat Rev; 1994 Jan; 20(1):11-49. PubMed ID: 7507404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of fluoropyrimidine derivatives].
    Fujii S; Shirasaka T
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2316-28. PubMed ID: 6238573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents.
    Tanaka F; Fukuse T; Wada H; Fukushima M
    Curr Pharm Biotechnol; 2000 Sep; 1(2):137-64. PubMed ID: 11467334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules.
    Kamm YJ; Wagener DJ; Rietjens IM; Punt CJ
    Anticancer Drugs; 1998 Jun; 9(5):371-80. PubMed ID: 9660532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry
    Adam C; Bray TL; Pérez-López AM; Tan EH; Rubio-Ruiz B; Baillache DJ; Houston DR; Salji MJ; Leung HY; Unciti-Broceta A
    J Med Chem; 2022 Jan; 65(1):552-561. PubMed ID: 34979089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.